Cadrenal Therapeutics Inc. (NASDAQ: CVKD) announced results from a Phase 2 trial of CAD-1005 for treating heparin-induced thrombocytopenia (HIT), according ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE